Canada (CA)

TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer (2017) Fagerholm R, Khan S, Schmidt MK, Garcia-Closas M, Heikkila P, Saarela J, Beesley J, et al. Journal article Prognostic implications of coronary artery calcium in the absence of coronary artery luminal narrowing (2017) Cho I, Hartaigh BO, Gransar H, Gransar H, Valenti V, Lin FY, Achenbach S, et al. Journal article Enhancement of Outflow Facility in the Murine Eye by Targeting Selected Tight-Junctions of Schlemm's Canal Endothelia (2017) Tam LCS, Reina-Torres E, Sherwood JM, Cassidy PS, Crosbie DE, Lütjen-Drecoll E, Flügel-Koch C, et al. Journal article Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4 (2017) Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, et al. Journal article Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study (2017) Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, et al. Journal article APREMILAST TREATMENT AND LONG-TERM (UP TO 156 WEEKS) IMPROVEMENTS IN DACTYLITIS AND ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF A LARGE DATABASE OF THE PHASE III CLINICAL DEVELOPMENT PROGRAM (2017) Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, et al. Conference contribution DURABILITY OF APREMILAST RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS: LONG-TERM (208-WEEK) RESULTS FROM THE PALACE 1 TRIAL (2017) Kavanaugh A, Gladman DD, Gomez-Reino JJ, Hall S, Lespessailles E, Mease PJ, Schett G, et al. Conference contribution The First Lanthanide Complexes with a Redox-Active Sulfur Diimide Ligand: Synthesis and Characterization of [LnCp*2(RN=)2S], Ln=Sm, Eu, Yb; R=SiMe3 (2017) Klementyeva SV, Gritsan NP, Khusniyarov M, Witt A, Dmitriev AA, Suturina EA, Hill NDD, et al. Journal article, Original article Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02) (2017) Siegel CA, Lichtenstein G, Siegmund B, Lewis JD, Wolf D, Louis E, Sebastian S, et al. Conference contribution Consistent Safety Profile with up to 4 Years of Apremilast Treatment: Analysis of Data from 1,493 Subjects with Psoriatic Arthritis in 3 Large, Phase III, Long-Term Studies (2017) Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, et al. Conference contribution